Introduction
Wiskott-Aldrich syndrome (WAS) is a rare X-linked disease in which immunodeficiency associates with thrombocytopenia and a high risk to develop tumors and autoimmune manifestations (1). Mutations in the WAS gene encoding a key regulator protein of the cytoskeleton lead to a defective expression of the molecule in hematopoietic cells (2). Besides immunodeficiency, autoimmunity represents a frequent clinical condition that, when present, increases the severity of the disease and defines a high-risk group with poor prognosis (3, 4). Combined studies in mice and patients have been performed to elucidate the contribution of WAS protein (WASp) in tolerance induction, particularly focusing on WASp-deficient T cells. Defects in peripheral tolerance caused by alterations in regulatory and effector T cell compartments have been demonstrated to play a major role in self-tolerance breakdown both in mouse models and patients (5) (6) (7) (8) . The analysis of Was -/-mice clearly points out defects in B cells, suggesting impairment in the removal of autoreactive B cells (9) (10) (11) . B cells from WAS patients show defects in migration and adhesion because of defective actin polymerization and poor migration toward S1P, as well as SDF1α (12) (13) (14) . B cell counts usually decrease with age in addition to a skewed distribution of serum immunoglobulins and impaired response to T cell-independent antigens (15, 16) . In addition, WASp plays an important role in the maintenance of B cell homeostasis in humans, as illustrated by the unusual expansion of CD21 -/lo B cells enriched in autoreactive clones in WAS patients irrespectively of age and disease severity scores (14, 17, 18) . Human WASp-deficient memory B cells showed a preferential usage of variable Ig heavy chain VH4-34, a gene segment encoding intrinsically self-reactive B cell receptors (BCRs) recognizing the I/i antigens (19, 20) and displayed reduced in vivo proliferation and decreased somatic hypermutation (14, 17) . Perturbations in B cell homeostasis in WAS patients led us to further assess whether the absence of WASp may impair B cell tolerance checkpoints responsible for the removal of developing autoreactive B cells (21) . A central B cell tolerance checkpoint, which depletes many polyreactive and antinuclear clones in the BM, appears to be mostly controlled by B cell intrinsic factors, since decreased BCR signaling and Toll-like receptor (TLR) 7 and 9 function lead to an impaired counterselection of autoreactive B cells (22) (23) (24) (25) . On the other hand, peripheral B cell tolerance is mostly regulated by B cell extrinsic factors, such as regulatory T cells (Treg) (24, (26) (27) (28) (29) . We thus investigated if the absence of WASp could affect central and peripheral B cell checkpoints, by evaluating the frequency of B cells expressing autoreactive antibodies at a single-cell level. We therefore analyzed the frequency of clones expressing polyreactive, HEp-2, or antinuclear antibodies (ANAs) in new emigrant/ Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency characterized by microthrombocytopenia, eczema, and high susceptibility to developing tumors and autoimmunity. Recent evidence suggests that B cells may be key players in the pathogenesis of autoimmunity in WAS. Here, we assessed whether WAS protein deficiency (WASp deficiency) affects the establishment of B cell tolerance by testing the reactivity of recombinant antibodies isolated from single B cells from 4 WAS patients before and after gene therapy (GT). We found that pre-GT WASp-deficient B cells were hyperreactive to B cell receptor stimulation (BCR stimulation). This hyperreactivity correlated with decreased frequency of autoreactive new emigrant/transitional B cells exiting the BM, indicating that the BCR signaling threshold plays a major role in the regulation of central B cell tolerance. In contrast, mature naive B cells from WAS patients were enriched in self-reactive clones, revealing that peripheral B cell tolerance checkpoint dysfunction is associated with impaired suppressive function of WAS regulatory T cells. The introduction of functional WASp by GT corrected the alterations of both central and peripheral B cell tolerance checkpoints. We conclude that WASp plays an important role in the establishment and maintenance of B cell tolerance in humans and that restoration of WASp by GT is able to restore B cell tolerance in WAS patients. (30, 31) . We found that WASp deficiency altered both central and peripheral B cell tolerance checkpoints and that lentiviral-mediated gene correction is highly efficient at restoring B cell tolerance in WAS patients. as compared with healthy donors (HDs) (4%-5.6% of clones, compared with 5%-11.5%) (Figure 1, A 
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-mature naive B cells from WAS patients (Supplemental Figure 4) . In contrast, the expressions of BCR-associated complex molecules CD19 and CD21 were found to be decreased on WASp-deficient mature naive B cells, revealing a differential regulation of cell-surface expression of BCRs and its coreceptor by WASp (Supplemental Figure 4) . Naive B cells from WAS patients also displayed a tendency to increase TACI and CD69 expression after TLR7 and TLR9 stimulation, although CD25 and CD86 regulation did not follow that (Supplemental Figure 1; Figure 2A and Supplemental Table 1 ). The reactivity of recombinant antibodies against dsDNA, insulin, and lipolysaccharide (LPS) was tested by ELISA assay to determine their polyreactivity, as previously described (Supplemental Tables 2-5) (21). We found that the proportion of polyreactive new emigrant/ transitional B cells was significantly decreased in all WAS patients Figure  6) . Hence, WASp deficiency is characterized by decreased Treg frequency associated with altered T cell homeostasis, suggesting Treg function may be impaired. CD45RO
+ Tregs that coexpress Ki67 were previously reported to express proinflammatory cytokines and to display reduced suppressive abilities (32) (33) (34) (35) . We therefore assessed Treg function by testing the capability of CD4 + CD25 hi CD127 lo T cells isolated from HDs and WAS patients to suppress the proliferation induced by beads coated with was further evidenced by the increased frequency of polyreactive mature naive B cells, which ranged from 10.5%-20.0% in WAS patients vs. 3.5%-13.6% in HDs ( Figure 3C Central B cell tolerance checkpoint is restored after HSC gene therapy in WAS patients. Lentiviral-mediated WAS gene transfer was recently shown to be a new therapy for WAS patients and restore lymphocyte development (30) . To assess whether newly generated B cells are normally selected in the BM after gene therapy (GT), we analyzed the reactivity of antibodies expressed by new emigrant/transitional B cells isolated from the same 4 WAS patients described above 1-2 years after GT (Supplemental Table 1 and Supplemental Figure 1 for gating strategy) (30) . All patients show a multilineage engraftment of transduced HSCs, with the WASp expression progressively increasing and persisting in the different hematopoietic cell lineages, likely reflecting a selective advantage in the periphery for WAS gene-corrected cells (31) . Differences in IgH repertoire from pre-GT WASp-deficient new emigrant/transitional B cells were no longer significant after GT when compared with HDs, suggesting an improvement in B cell selection in the BM (Supplemental Figure 2 ). We found that new emigrant/transitional B cells isolated from patients after GT expressed a proportion of polyreactive antibodies that was now similar to that of HDs, suggesting that central B cell tolerance was better established after GT ( Figure 5, A Tables 14-17 ). These frequencies after GT display averages within the 16%-26.3% HD range, suggesting that the peripheral B cell selection step may be functional in the presence of lentiviral-encoded functional WASp ( Figure 6, A and B) . A tendency to the normalization of the peripheral B cell tolerance checkpoint was further evidenced by the decreased frequency of polyreactive clones in the mature naive B cell compartments in 3 out of 4 patients after GT, reaching values comparable to those in HDs (Figure 6C and Supplemental Figure 7 ). Of note, ANAexpressing clones remained rare after GT ( Figure  6, D and E) , and the few cytoplasm-reactive clones were weakly positive by immunofluorescence ( Figure 6D ). Interestingly, Treg function, which plays an important role in the regulation of this peripheral B cell tolerance checkpoint (24, 26) , was found restored in 2 WAS patients after GT while Treg frequencies before and after GT appeared similar (Figure 7 , A-C) (30) . In agreement with this observation, we found a decreased Ki67 expression by Tregs and other T cells from WAS patients after GT, revealing a normalization of the homeostasis of these T cell compartments by the expression of functional WASp (Figure 7, D and E) . Thus, GT restores the functionality of the peripheral B cell tolerance checkpoint in WAS patients, correlating with the correction of Treg suppression defects observed after GT treatment.
Discussion
We report here that WAS patients suffer from dysregulated central and peripheral B cell tolerance checkpoints, which are restored after lentiviral-mediated WAS gene transfer. Hence, The proportion of polyreactive antibodies after GT was slightly increased compared with their B cell counterparts before GT (5%-15.8% in WAS patients after GT compared with 5%-11.5% in HDs), although differences did not reach statistical significance. Correction by GT of the enhanced removal of developing autoreactive B cells in the BM was further evidenced by the significant increase in the frequency (30%-42.1%) of HEp-2-reactive new emigrant/transitional B cells in WAS patients after GT compared with 16.7%-21.7% in the patients before treatment ( Figure 5, C and D) . These proportions of HEp-2-reactive new emigrant/transitional B cells after GT were now similar to those (29.2%-44.7%) of HDs ( Figure 5, C and D) . No difference was observed in the frequency of ANA + B cell clones before and after GT, which remained virtually undetectable ( Figure 5E ). We conclude that the restoration of WASp expression in HSCs of WAS patients after GT leads to the normalization of the central B cell tolerance checkpoint. who displayed decreased frequencies of Tregs, nonfunctional Tregs, or both (24, 26, 27, 29) . In agreement with these data, the defective peripheral B cell tolerance checkpoint in WAS patients was associated with Tregs displaying an abnormal phenotype and showing defect in homeostasis regulation and suppressive capacities. WAS patients' Tregs exhibited an activated phenotype illustrated by increased CTLA4 expression and contained an increased proportion of Ki67 + proliferating clones in the patients' CD45RO + Tregs, a feature associated with proinflammatory cytokine production combined with reduced suppressive capabilities (32) (33) (34) (35) . Indeed, CD4 + CD25 hi CD127 lo Tregs from WAS patients showed impaired suppressive activity, further supporting previous observations obtained with CD4 + CD25 hi T cells (5-8) . In particular, it has been demonstrated that Tregs lacking WASp showed a reduced ability to suppress B cell activation and proliferation (40) , thus suggesting that Treg failure could contribute to the altered B cell tolerance observed in WAS patients and mouse counterparts. While WAS mutations enhance BCR/ TLR functions, many reports demonstrated decreased T cell receptor responses (TCR responses), including diminished IL-2 production in WASp-deficient T cells (41) (42) (43) . Hence, decreased TCR responsiveness and IL-2 production in WAS patients may also be responsible for their abnormal Treg function. We conclude that the defective peripheral B cell tolerance checkpoint in WAS patients is likely explained by qualitative defects in Tregs in the absence of functional WASp.
HSC-GT using lentiviruses has recently been reported to improve WAS patients' clinical condition and results in robust and stable multilineage engraftment of transduced cells (30) . In addition to this quantitative reconstitution of hematopoietic lineages including B cells, we found that HSC-GT restores both central and peripheral B cell tolerance checkpoints. HSC-GT also corrected the abnormal central and peripheral B cell tolerance in ADA-SCID patients, further supporting the qualitative efficacy of this treatment (22) (23) (24) 36) . Since central B cell tolerance requires proper BCR and TLR function, our data suggest that gene correction of WASp-deficient B cells by lentiviral HSC-GT may lead to the normalization of BCRs, thereby reestablishing proper thresholds for the removal of developing autoreactive B cells. As a consequence, HSC-GT results in a decreased proportion of new emigrant/transitional B cells exiting the BM that was reported to be increased in WAS patients (31) . HSC-GT also corrected the second B cell selection step that occurs between new emigrant/transitional and mature naive B cell stages. The restoration of Treg function in WAS patients after GT correlates with proper peripheral B cell selection and prevents the accumulation of autoreactive clones in their blood, further revealing that Tregs are responsible for the regulation of this peripheral checkpoint (24, 26, 29) . As part of tolerance restoration, the global homeostasis of T cell compartments, including Tregs, was improved in WAS patients after GT, as illustrated by the decreased expression of Ki67 proliferation marker by their T cells, likely resulting from the presence of functional Tregs.
In summary, we demonstrated that WASp plays an essential role in the establishment of early B cell tolerance in humans and that lentiviral-mediated gene correction of WASp restores both central and peripheral B cell tolerance checkpoints in WAS patients.
WASp plays an important role in the regulation of these early developmental steps responsible for the selection of B cells and their antibody repertoire.
The regulation of central B cell tolerance appears to involve intrinsic B cell molecules involved in sensing binding to self-antigens and which include BCRs and potentially TLRs (25) . Indeed, alterations in BCR signaling and/or TLR function in immunodeficient patients with mutations in genes encoding Bruton's tyrosine kinase, adenosine deaminase (ADA), IRAK4, MYD88, or TACI result in defective B cell responses to these receptors and correlate with the impaired removal of developing autoreactive clones that escape central B cell tolerance (22) (23) (24) 36) . In contrast, all WAS patients before HSC-GT displayed a more stringent central B cell tolerance checkpoint, as evidenced by the enhanced removal of developing autoreactive clones that expressed either polyreactive or HEp-2-reactive antibodies. The first identification in humans, to our knowledge, of a hyperactive counterselection step for autoreactive clones in the BM of WAS patients correlates with their enhanced BCR function. These findings further support the model in which BCR binding to self-antigens plays a key role in the induction of tolerance mechanisms, such as receptor editing or deletion, leading to the silencing of autoreactive B cells. The modest increase in TLR7 and TLR9 responses in human WASp-deficient B cells is a feature that has been previously reported in murine B cells, as well as plasmacytoid DCs (9, 37) , and that may also contribute to the increased removal of autoreactive clones at the central B cell tolerance checkpoint. In conclusion, WASp expression in developing B cells is important to establish proper thresholds for autoreactive B cell silencing in the BM.
WASp is a regulator of actin dynamics and may therefore affect the signaling and trafficking of BCRs and TLRs (38, 39) . Actin remodeling is associated with BCR signaling and requires Vav, PLCγ2, and Btk, which activate the Rho family GTPases Rac and Cdc42 that bind WASp (38, 39) . The absence of functional WASp may therefore interfere with actin remodeling and result in increased BCR function. In line with this hypothesis is the decreased BCR internalization that correlated with increased calcium mobilization in mouse B cells harboring a specific deletion of WASp (9) . Interestingly, we found increased BCR expression on mature naive B cells from WAS patients. Thus, the absence of functional WASp results in increased BCR signaling, which likely affects the removal of developing autoreactive B cells and B cell activation at later stages of B cell development.
The more stringent central B cell tolerance checkpoint and the dearth of autoreactive immature B cells exiting the BM of WAS patients appeared paradoxical because these patients are characterized by a break in B cell tolerance and the production of autoreactive antibodies (4). However, we found that WAS patients also suffer from an impaired peripheral B cell tolerance checkpoint, resulting in an increase in autoreactive clones in their mature naive B cell compartment. This emergence of polyreactive and HEp-2-reactive B cells between the new emigrant/transitional and mature naive B cell stages reveals that these self-reactive clones are positively selected in the absence of functional WASp. A similar faulty selection of mature naive B cells was observed in CD40L-, FOXP3-, and DOCK8-deficient patients, as well as in patients with common-variable immunodeficiency jci. Statistics. Differences between patients and HDs were analyzed for statistical significance using the Mann-Whitney test. Differences between samples before and after GT were analyzed using paired t tests. A P value less than 0.05 was considered significant.
Study approval. All samples were collected in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and institutional review board-reviewed protocols. GT studies refer to the clinical protocol (ClinicalTrials.gov, NCT01515462) whose criteria of eligibility have been previously described (30) . All legal representatives gave written informed consent.
Methods
Patients. Characteristics of WAS patients treated by GT are described in Supplemental Table 1 . GT for WAS was performed as previously described (30) . The 4 WAS patients treated by GT, described in this study, are reported in the same order in Aiuti WAS mutation and Zhu scores of 5A and 2, respectively; WAS52 (12 years old) with c.820-835dup16 WAS mutation and a Zhu score of 2; WAS58 (3 years old) with c.778-6G>A WAS mutation and a Zhu score of 2; and WAS patients Y2 (2 years old), Y6 (9 years old), and Y7 (76 years old) with pHis30del WAS mutation and Zhu scores of 2, 2, and 4, respectively. HDs were previously reported, except HD30, who is a 47-year-old female of mixed European descent (Supplemental Tables 18 and 19) .
Cell staining and sorting. Peripheral B cells were purified from the blood of patients and HDs by positive selection using CD20-magnetic beads (Miltenyi Biotec). Enriched B cells were stained with the following antibodies: anti-CD19-Pacific Blue (clone HIB19), anti-CD27-PercP-Cy5.5 (clone O323), anti-CD10-PE-Cy7 (clone HI10a) (all from BioLegend), anti-CD21-APC (clone B-ly4), and anti-IgM-FITC (clone G20-127) (from BD Biosciences). Single CD19 5 μl reactions containing 100 U Superscript II RT (Invitrogen) for 45 minutes at 42°C. Reverse transcription PCR (RT-PCR) reactions, primer sequences, cloning strategy, expression vectors, antibody expression, and purification were performed as previously described (21, 44) . Antibody reactivity was tested by ELISA as previously described (21, 44) . Highly reactive ED38 was used as positive control in HEp-2 reactivity and polyreactivity ELISA (21, 44) . Antibodies were considered polyreactive when they recognized all 3 analyzed antigens: dsDNA, insulin, and LPS. For indirect immunofluorescence assays, HEp-2 cell-coated slides (BION Enterprises Ltd.) were incubated in a moist chamber at room temperature with purified antibodies at 50-100 μg/ml and detected using FITC-conjugated goat anti-human IgG.
B cell activation assay. Naive B cells were seeded in 384-well flat-bottom plates at a concentration of 50,000 cells/well in RPMI 10% FBS and 2 μg/ml or 0.7 μg/ml F(ab′) 2 rabbit anti-human IgM (Jackson ImmunoResearch Laboratories Inc.), 2 μg/ml or 0.75 μg/ml gardiquimod (InvivoGen), or 0.5 μg/ml or 0.3 μg/ml CpG ODN2006 (Invitrogen) for 2 days. Flow cytometry analysis was performed using anti-CD25-FITC (clone BC96), anti-CD86-APC (clone IT2.2), anti-TACI-PE (clone 1A1), anti-CD69-PE-Cy7 (clone FN50), anti-CD27-PerCP-Cy5.5 (clone O323), anti-CD19 APC-Cy7 (clone HIB19) (all BioLegend), and anti-CD21-Pacific Blue (clone B-ly4, BD Biosciences).
In vitro Treg suppression assay. CD4 + T cells were enriched using the EasySep Human CD4 + T cell enrichment kit (StemCell Technologies Inc.). Only in the case of pre-and post-GT samples of patient WAS2, the jci.org Volume 125 Number 10 October 2015
